![An open label six month study to evaluate the safety and efficacy of nitrogen mustard (NM) [chlormethine] 0.04% ointment formulation in patients with stage I or IIA mycosis fungoides (MF) who have completed an initial 12 month treatment with nitrogen mustard 0.02% but without a complete response.](https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/Adis_logo.png "An open label six month study to evaluate the safety and efficacy of nitrogen mustard (NM) [chlormethine] 0.04% ointment formulation in patients with stage I or IIA mycosis fungoides (MF) who have completed an initial 12 month treatment with nitrogen mustard 0.02% but without a complete response."){kind=logo}
Trial Profile
An open label six month study to evaluate the safety and efficacy of nitrogen mustard (NM) [chlormethine] 0.04% ointment formulation in patients with stage I or IIA mycosis fungoides (MF) who have completed an initial 12 month treatment with nitrogen mustard 0.02% but without a complete response.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Chlormethine (Primary)
- Indications Mycosis fungoides
- Focus Therapeutic Use
- Sponsors Actelion Pharmaceuticals
- 10 May 2022 Results of post-hoc analysis published in the American Journal of Clinical Dermatology.
- 18 Feb 2021 According to a Helsinn Therapeutics media release, it is pleased to note two recent journal publications on the use of mechlorethamine gel 0.016% as a topical treatment of early stage mycosis fungoides-type cutaneous T-cell lymphoma . Bioanalytic testing results indicate lack of systemic absorption of mechlorethamine in plasma samples from the 201 and 202 pivotal study.
- 06 Dec 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.